A Phase 1b, Open-label Single dose study to Evaluate the Pharmacokinetics, Safety and Tolerability of MK-7655A in Pediatric Subjects from Birth to less than 18 years of Age with Confirmed or Suspected Gramnegative Infections

Administered By

Awarded By

Contributors

Start/End

  • August 16, 2017 - September 30, 2020